Loading...
XWAR
CLN
Market cap322mUSD
Sep 19, Last price  
21.70PLN
1D
0.00%
1Q
0.46%
IPO
-31.29%
Name

Celon Pharma SA

Chart & Performance

D1W1MN
P/E
—
P/S
6.62
EPS
—
Div Yield, %
0.37%
Shrs. gr., 5y
3.14%
Rev. gr., 5y
11.55%
Revenues
177m
+7.44%
40,109,16171,640,12598,099,063107,540,270128,777,939107,120,079125,244,805102,247,205139,270,000169,559,000161,915,000164,394,000176,618,000
Net income
-34m
L+22.48%
1,333,50817,957,73252,207,12037,180,21537,807,41925,615,33229,697,10411,934,95821,495,000-11,607,000-39,277,000-28,124,000-34,447,000
CFO
-11m
L+36.38%
12,866,6868,450,09924,358,09952,368,29120,645,69925,302,74528,240,315070,904,00043,952,000-4,701,000-8,314,000-11,339,000
Dividend
Jun 27, 20240.08 PLN/sh

Profile

Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets pharmaceutical products and preparations. The company operates through Generic Drug and Innovative segments. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.
URL
https://celonpharma.com/
IPO date
Dec 01, 2016
Employees
521
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
176,618
7.44%
164,394
1.53%
161,915
-4.51%
Cost of revenue
63,171
67,499
129,461
Unusual Expense (Income)
NOPBT
113,447
96,895
32,454
NOPBT Margin
64.23%
58.94%
20.04%
Operating Taxes
(4,921)
8,156
2,831
Tax Rate
8.42%
8.72%
NOPAT
118,368
88,739
29,623
Net income
(34,447)
22.48%
(28,124)
-28.40%
(39,277)
238.39%
Dividends
(4,085)
(4,595)
(14,800)
Dividend yield
0.29%
0.58%
2.07%
Proceeds from repurchase of equity
40,510
2
4
BB yield
-2.92%
0.00%
0.00%
Debt
Debt current
8,672
19,880
19,434
Long-term debt
23,652
(4,337)
34,210
Deferred revenue
22,884
Other long-term liabilities
359
5,810
4,146
Net debt
(24,195)
(28,231)
(42,503)
Cash flow
Cash from operating activities
(11,339)
(8,314)
(4,701)
CAPEX
(22,792)
(32,813)
(33,906)
Cash from investing activities
(7,494)
(21,640)
(31,472)
Cash from financing activities
13,323
(20,589)
(28,721)
FCF
123,802
52,985
52,037
Balance
Cash
56,519
114,543
164,624
Long term investments
(70,769)
(68,477)
Excess cash
47,688
35,554
88,051
Stockholders' equity
(109,572)
(97,676)
479,646
Invested Capital
572,064
597,516
422,563
ROIC
20.24%
17.40%
6.84%
ROCE
24.38%
19.27%
6.34%
EV
Common stock shares outstanding
52,522
51,056
51,024
Price
26.45
71.09%
15.46
10.27%
14.02
-57.71%
Market cap
1,389,196
76.00%
789,333
10.34%
715,362
-53.77%
EV
1,365,001
761,102
672,859
EBITDA
165,306
146,911
76,549
EV/EBITDA
8.26
5.18
8.79
Interest
2,472
2,662
1,671
Interest/NOPBT
2.18%
2.75%
5.15%